Anti-Angiogenic Therapy for Malignant Glioma: Insights and Future Directions

Province, Paula; Han, Xiaosi; Nabors, Louis B.; Fathallah‐Shaykh, Hassan M.

doi:10.5772/23021

Search citation statements

Order By: Relevance

Paper Sections

Select...

Implications For Treatment Of Malignant Gliomas1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Book1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 65 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as a result of blood-brain barrier stabilization secondary to anti-angiogenic agents, contrast enhancement is no longer a reliable measure of progression. Therefore, the Response Assessment in Neuro-Oncology (RANO) Working Group developed the RANO criteria as a means to address potential progression by non-enhancing T2/FLAIR (fluid attenuated inversion recovery) lesions as well as by increases in contrast enhancement in malignant gliomas (Province, Han et al 2011). The use of anti-angiogenic agents, namely Bevacizumab, has also raised many questions about patterns of recurrence in malignant gliomas.…”

Section: Implications For Treatment Of Malignant Gliomasmentioning

confidence: 99%